Novo Nordisk’s Thomsen Says IDegLira Data ‘Unprecedented’

June 14, 2014 10:36 PM

7 0

Novo Nordisk A/S (NOVOB)’s combination of a new insulin with its established Victoza therapy lowered blood-sugar to unprecedented levels and should be an important diabetes treatment once approved, Chief Science Officer Mads Krogsgaard Thomsen said.

Late-stage trial results presented at the American Diabetes Association in San Francisco showed that IDegLira, a once-daily injection combining Tresiba, Novo Nordisk’s new insulin, and Victoza lowered blood sugar more than each medicine taken on its own, Novo said in an e-mail today.

Also read: U.N. Warns of Humanitarian Crisis in Mosul

Read more

To category page